Literature DB >> 11594582

Reversible resistance to apoptosis in cutaneous T cell lymphoma.

S J Meech1, R Edelson, P Walsh, D A Norris, R C Duke.   

Abstract

Mycosis fungoides and its leukemic variant, Sézary syndrome, represent the most common forms of cutaneous T cell lymphomas (CTCL). These disorders are clonal neoplasms characterized by the progressive accumulation of cells that resemble activated/memory CD4+ T cells. Unlike their normal counterparts, these malignant lymphocytes have prolonged life spans and are resistant to dying following treatment with most chemotherapeutic agents. This suggests that CTCL undergo abnormal programmed cell death; however, data regarding apoptotic defects in CTCL are limited. Regulation of apoptosis in lymphocytes that regularly undergo clonal expansion is necessarily complex and will be reviewed here. Clonally expanded lymphocytes rely primarily on Fas-mediated pathways to initiate apoptosis. Factors leading to the resistance of apoptosis in CTCL and new therapeutic approaches for reversing this resistance will be discussed, including the important role that the Fas death pathway may play in the pathogenesis and treatment of CTCL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594582     DOI: 10.1111/j.1749-6632.2001.tb03710.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

Authors:  Jianqiang Wu; Jawed Siddiqui; Minakshi Nihal; Eric C Vonderheid; Gary S Wood
Journal:  Arch Biochem Biophys       Date:  2010-10-29       Impact factor: 4.013

Review 2.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

3.  Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.

Authors:  Karthik M Kodigepalli; Minghua Li; Shan-Lu Liu; Li Wu
Journal:  Cell Cycle       Date:  2016-12-08       Impact factor: 4.534

4.  Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70.

Authors:  K Ferenczi; J Ohtola; P Aubert; M Kessler; H Sugiyama; A K Somani; A C Gilliam; J Z Chen; I Yeh; S Matsuyama; T S McCormick; K D Cooper
Journal:  Br J Dermatol       Date:  2010-09       Impact factor: 9.302

5.  Over-expressed Fas improves the apoptosis of malignant T-cells in vitro and vivo.

Authors:  Linghao Li; Ri Zhang; Zixing Chen; Shengli Xue; Xiuli Wang; Changgeng Ruan
Journal:  Mol Biol Rep       Date:  2011-03-11       Impact factor: 2.316

6.  Pharmacogenetic contribution of leptin gene polymorphism in cutaneous T-cell lymphoma.

Authors:  Vladimir Vasku; Anna Vasku; Julie Bienertova Vasku
Journal:  Int J Clin Exp Pathol       Date:  2008-07-18

7.  Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.

Authors:  Jianqiang Wu; Gary S Wood
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 8.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.

Authors:  Joseph S Durgin; David M Weiner; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

9.  Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.

Authors:  Leigh Ellis; Roberto Pili
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-01

10.  Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.

Authors:  H Yao; E Song; J Chen; P Hamar
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.